PRTN3 and rheumatoid arthritis: Anti-citrullinated peptide antibodies (ACPA)-negative (ACPA−) rheumatoid arthritis (RA) presents significant diagnostic and therapeutic challenges due to the absence of specific biomarkers, underscoring the need to elucidate its distinctive cellular and metabolic profiles for more targeted interventions.